Deforolimus

Drugbox
IUPAC_name =

---

CAS_number = 572924-54-0
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
C=53 | H=84 | N=1 | O=14 | P=1
molecular_weight =
smiles =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Deforolimus (also known as AP23573 and MK-8669) is an immunosupressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

Deforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. As of 2008, a phase III clinical trial of deforolimus in metastatic soft-tissue and bone sarcomas responsive to chemotherapy, SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus), is recruiting patients. [cite web | url = http://www.ariad.com/wt/page/succeed | title = SUCCEED: Landmark Global Phase 3 Trial Now Enrolling! | publisher = ARIAD Pharmaceuticals | accessdate = 2008-04-18 | year = 2008] [ [http://clinicaltrials.gov/ct2/show/NCT00538239 Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study.] ClinicalTrials.gov (2008-03-07). Retrieved on 2008-04-18.]

References

External links

* [http://www.ariad.com ARIAD Pharmaceuticals]